818 related articles for article (PubMed ID: 27893836)
1. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
2. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
[TBL] [Abstract][Full Text] [Related]
4. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma].
Li ZQ; Tian WW; Guo YF; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
7. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
[TBL] [Abstract][Full Text] [Related]
8. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
[TBL] [Abstract][Full Text] [Related]
10. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
[TBL] [Abstract][Full Text] [Related]
11. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
12. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
14. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
[TBL] [Abstract][Full Text] [Related]
15. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Holzhey T; Pönisch W; Wang SY; Holzvogt M; Holzvogt B; Andrea M; Zehrfeld T; Hammerschmidt D; Hoffmann FA; Becker C; Schwarzer A; Schwarz M; Schönfelder-Fricke U; Edelmann T; Braunert L; Franke GN; Jentzsch M; Schwind S; Bill M; Grimm J; Remane Y; Platzbecker U; Scholz M
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2349-2359. PubMed ID: 33433659
[TBL] [Abstract][Full Text] [Related]
17. Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
Mohammed N; Chandran PA; Kandregula M; Mattaparthi RD; Gundeti S; Volturi J; Darapuneni R; Raju SB; Dattatreya PS
Asian Pac J Cancer Prev; 2016; 17(5):2605-10. PubMed ID: 27268638
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.
Fukumoto K; Fujisawa M; Suehara Y; Narita KT; Usui Y; Takeuchi M; Matsue K
Leuk Lymphoma; 2016 Aug; 57(8):1786-92. PubMed ID: 26764045
[TBL] [Abstract][Full Text] [Related]
20. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
